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BACKGROUND AND PURPOSE
Mice with functional ablation of substance P-preferring neurokinin-1 receptors (NK1R−/− mice) display behavioural
abnormalities resembling those in attention deficit hyperactivity disorder (ADHD). Here, we investigated whether the ADHD
treatment, guanfacine, alleviated the hyperactivity and impulsivity/inattention displayed by NK1R−/− mice in the light/dark
exploration box (LDEB) and 5-choice serial reaction–time task (5-CSRTT), respectively. Following reports of co-morbid anxiety
in ADHD, we also investigated effects of guanfacine on anxiety-like behaviour displayed by NK1R−/− and wild-type (WT) mice
in the elevated plus maze (EPM).
EXPERIMENTAL APPROACH
Mice were treated with guanfacine (0.1, 0.3 or 1.0 mg·kg−1, i.p.), vehicle or no injection and tested in the 5-CSRTT or the
LDEB. Only the lowest dose of guanfacine was used in the EPM assays.
KEY RESULTS
In the 5-CSRTT, a low dose of guanfacine (0.1 mg·kg−1) increased attention in NK1R−/− mice, but not in WT mice. This dose
did not affect the total number of trials completed, latencies to respond or locomotor activity in the LDEB. Impulsivity was
decreased by the high dose (1.0 mg·kg−1) of guanfacine, but this was evident in both genotypes and is likely to be secondary
to a generalized blunting of behaviour. Although the NK1R−/− mice displayed marked anxiety-like behaviour, guanfacine did
not affect the behaviour of either genotype in the EPM.
CONCLUSIONS AND IMPLICATIONS
This evidence that guanfacine improves attention at a dose that did not affect arousal or emotionality supports our proposal
that NK1R−/− mice express an attention deficit resembling that of ADHD patients.
LINKED ARTICLES
This article is part of a themed section on Animal Models in Psychiatry Research. To view the other articles in this section visit
http://dx.doi.org/10.1111/bph.2014.171.issue-20
Abbreviations
5-CSRTT, 5-choice serial reaction–time task; ADHD, attention deficit hyperactivity disorder; DZ, dark zone; EPM,
elevated plus maze; KO, knockout; LDEB, light/dark exploration box; LZ, light zone; VITI, variable inter-trial interval;
WT, wild-type
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Tables of Links
TARGETS LIGANDS
α2A-adrenoceptors d-Amphetamine Methylphenidate
NK1 receptors Guanfacine RP 67580
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (Alexander et al., 2013).
Introduction
Mice from a 129/Sv × C57BL/6J genetic background (crossed
with an outbred MF1 strain), with functional ablation of the
substance P-preferring, neurokinin-1 (NK1) receptor gene
(referred to as NK1R−/−mice) (de Felipe et al., 1998), express
locomotor hyperactivity in an activity meter (Herpfer et al.,
2005) and the light/dark exploration box (LDEB) (Herpfer
et al., 2005; Fisher et al., 2007; Yan et al., 2010). They also
display deficits in cognitive performance and response
control when tested in the 5-choice serial reaction–time task
(5-CSRTT). Specifically, when compared with their wild-type
(WT) counterparts, they typically score greater %omissions
(an index of inattentiveness) and increased %premature
responses (an index of motor impulsivity) in this test (Yan
et al., 2011; Dudley et al., 2013). Mechanism(s) that could
explain how a lack of functional NK1 receptors could provoke
locomotor hyperactivity, inattentiveness and impulsivity are
reviewed in Yan et al. (2010) and Stanford (2014).
These abnormal behaviours (hyperactivity, inattention
and impulsivity) resemble the core diagnostic features of
attention deficit hyperactivity disorder (ADHD). Our proposal
that NK1R−/− mice can be used to study the behavioural and
cognitive abnormalities seen in ADHD patients is supported
by evidence from translational studies, which discovered that
an association between polymorphisms in, or near, the
human equivalent of the NK1 receptor gene (TACR1) predicts
increased vulnerability to ADHD (Sharp et al., 2009; 2014;
Yan et al., 2010).
Psychomotor stimulants (d-amphetamine, methylpheni-
date and the prodrug, lisdexamfetamine) are the first-line
treatments for ADHD. Only two other compounds are
licensed for this clinical indication: the preferential
noradrenaline reuptake inhibitor, atomoxetine (Preti, 2002),
and the α2A-adrenoceptor agonist, guanfacine (Biederman
et al., 2008; Sallee et al., 2009). An extended release formula-
tion of guanfacine was approved for the treatment of ADHD
in the United States in 2009.
We have reported previously that the hyperactivity of
NK1R−/− mice is attenuated by the psychostimulants,
d-amphetamine and methylphenidate, as in ADHD (Yan
et al., 2009; 2010), but d-amphetamine did not prevent
impulsivity or inattentiveness in the 5-CSRTT (Yan et al.,
2011). This could be relevant to reports that d-amphetamine
is ineffective in about 25% of ADHD patients (Heal et al.,
2009). The first objective of this study was to investigate
whether guanfacine ameliorates the deficits in cognitive per-
formance or response control that are expressed by NK1R−/−
mice in the 5-CSRTT, in line with its efficacy in treating
ADHD.
A second objective was to establish whether or not guan-
facine prevents the locomotor hyperactivity of NK1R−/−
mice. It has already been reported that this drug reduces
locomotor activity of the SHR (an established rodent model
of ADHD) in the open field, but not that of their control
strains (Wistar or Wistar Kyoto; Langen and Dost, 2011).
However, we were mindful of the problem that animals’ emo-
tional status (anxiety-like behaviour) can confound measures
of locomotor activity in this test (see Stanford, 2007a,b;
Wilcock and Broadhurst, 1967). This is especially important
for studies of the effects of guanfacine on motor behaviour
because this drug is used to treat anxiety, which is a common
co-morbid disorder in ADHD (Sobanski, 2006). For that
reason, we also compared the effects of guanfacine on the
behaviour of NK1R−/− mice and WT in the elevated plus
maze (EPM), an established screen for anxiolytic drugs.
A final caveat is that, although NK1R−/− mice display
inattention and impulsivity when they derive from separate
homozygous, inbred strains (‘homs’), the behavioural pheno-
type of homozygous progeny from heterozygote NK1R+/−
(F1) breeding pairs (‘hets’) is as yet unknown. This, together
with growing interest in epigenetic influences in ADHD,
prompted us to investigate whether any effects of guanfacine
on behaviour in the 5-CSRTT differ in WT and NK1R−/− mice
derived from these two breeding methods.
The findings from these studies lead us to infer that a low
dose of guanfacine (0.1 mg·kg−1) reduces inattentiveness of
NK1R−/− mice in the 5-CSRTT, but that higher doses
(10 mg·kg−1) reduce impulsivity in both genotypes. The latter
response to guanfacine is likely to be a consequence of the
sedative effects of this drug. Neither of these responses
to guanfacine is dependent on the breeding method nor is
likely to be explained by any change in animals’ emotional
status.
Methods
Animals
All animal care and experimental procedures complied with
the Animals (Scientific Procedures) Act, 1986 (UK) and were
approved by the Ethical Review Panel at University College
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London. These studies comply with the ARRIVE guidelines
for reporting experiments involving animals (Kilkenny et al.,
2010; McGrath et al., 2010). A total of 104 animals were used
in these experiments (24 in the 5-CSRTT, 50 in the LDEB and
30 in the EPM).
Mouse colonies were bred at University College London in
a facility held at 21 ± 2°C, 45 ± 5% humidity, with a 12:12 h
light : dark cycle (lighting increased in steps from 07:00 to
08:00 h and reduced in steps from 19:00 to 20:00 h). The
home cages incorporated environmental enrichment and
were cleaned twice weekly (bedding obtained from Litaspen
Premium, Lillico, Horley, Surrey, UK). Food supply was
obtained from Harlan (Bicester, UK: 2018 global rodent diet).
All mice were bred from the same background strain
(129/Sv × C57BL/6J crossed with an outbred MF1 strain, more
than 10 generations ago) (de Felipe et al., 1998). Half of the
mice used in the 5-CSRTT experiment comprised homozy-
gous WT (NK1R+/+) and NK1R−/− mice from inbred homozy-
gous parents (homs) (N = 6 per group). The subjects were the
progeny from two breeding pairs for each genotype. The
remainder, which were tested at the same time as the homs,
comprised (F2) homozygous WT and NK1R−/− mice derived
from three breeding pairs of heterozygous (NK1R+/−) parents,
which were the (F1) progeny of inbred WT (NK1R+/+) mice
crossed with inbred NK1R−/− mice (WT hets and NK1R−/−
hets) (N = 6 per group).
Each home cage contained two to four mice. The wild-
type and NK1R−/− homs were housed separately, but het mice
were housed in cages that contained at least one WT and one
NK1R−/− mouse. Only mice from homozygous parents
(inbred strains) were used in the LDEB and EPM because there
were no differences in the effects of guanfacine on the behav-
iour of the two colonies of mice in the 5-CSRTT.
5-CSRTT
Twelve WT male and 12 NK1R−/− male mice were used at 6–8
weeks of age (weighing WT hom: 30.5–35.6 g; NK1R−/− hom:
26.7–30.9 g; WT het: 31.1–41.1 g; NK1R−/− het: 30.5–34.7 g at
the start of training). The mice were brought into the labo-
ratory every day (Monday to Friday) between 09:00 and
09:30 h and weighed before training/testing in the 5-CSRTT,
which took place between 10:00 and 12:00 h (AM session) or
13:00 and 15:00 h (PM session). The animals were returned to
the holding room at 16:00 h and each cage supplied with a
weighed quota of food, which was adjusted to stabilize sub-
jects at 90% of their free-feeding body weight. Water was
freely available at all times. One WT het and one NK1R−/− het
failed to graduate through the training phase of the proce-
dure and were withdrawn from the study.
The apparatus, supplied by Med Associates (St. Albans, VT,
USA), was controlled by a Smart Ctrl Package 8IN/16OUT with
an additional interface by MED-PC for Windows (Med Asso-
ciates). This comprised four sound-attenuated operant cham-
bers with five equally spaced apertures, incorporated into one
wall of each chamber: these apertures could be illuminated
independently. A nose-poke by the mice into each hole was
scored following interruption of an infrared beam that
spanned the hole. Interceptions of an infrared beam across a
magazine in the opposite wall, which delivered the reward
(0.01 mL of 30% condensed milk solution), were also scored:
these occurred whenever a mouse collected the reward and
initiated the next ‘trial’. Incorrect, omitted and premature
responses were punished with a 5 s time out, during which the
house light was extinguished and no new trials could be
initiated. Perseverative responses were not punished.
The procedure was the same as that previously reported
and is documented in full elsewhere (Yan et al., 2011). Briefly,
mice were assigned to one of four test chambers in a fully
counterbalanced design and were tested in the same chamber
throughout. First, they were habituated to the apparatus for 3
days and then trained in the 5-CSRTT, graduating through
increasingly challenging stages (1–6) after fulfilling the crite-
ria for each stage (see Yan et al., 2011). The final stimulus
duration (SD) at stage 6 was 1.8 s. After reaching the criteria
for a stable baseline at stage 6 (total trials completed minus
premature responses = 100; >75% accuracy; <25% omissions),
for at least 3 consecutive days, the mice were eligible for
testing with a variable inter-trial interval [VITI; 2, 5, 10 or 15 s
(delivered on a random schedule) with an SD of 1.8 s]. Mice
were tested with the VITI once weekly, on Fridays. A VITI test
was used because it prevents the use of interval timing as a
strategy for correct responding, thereby increasing cognitive
load. The first week of testing was carried out with treatment–
naïve mice [no injection (1): ‘NI-1′] only (reported else-
where). In each of the following 5 weeks, mice were subject to
a VITI test, 30 min after an i.p. injection of either vehicle
(saline, 10 mL·kg−1) or guanfacine (0.1, 0.3 or 1.0 mg·kg−1), or
a second untreated session [no injection (2): ‘NI-2′]. These
drug doses were chosen because they modify relevant aspects
of behaviour in mice: for example, working memory in a
T-maze (Franowicz et al., 2002) and locomotor activity
(Archer and Fredriksson, 2003). NI-2 (baseline behaviour of
uninjected mice) was embedded within the sequence of
vehicle/drug treatments to control for any systematic
changes in behaviour arising from rehearsal of the test (see
Weir et al., 2014). The vehicle/drug/NI-2 sessions were coun-
terbalanced across subjects, using a pseudo William’s Latin
square, such that each mouse received each treatment, or
NI-2 session, once only.
The test sessions were terminated after either 45 min or
after the mouse completed 100 trials, plus the number of
premature responses, whichever occurred first. Performance
scores in the 5-CSRTT were recorded and stored online (see
Table 1). Omissions and premature responses were calculated
per 100 trials to correct for any differences in the total
number of trials completed by the mice.
LDEB
A separate cohort of NK1R−/− and WT mice, from homozy-
gous breeding pairs, was tested in the LDEB, which was dimly
lit [dark zone (DZ): 4 lux, light zone (LZ): 20 lux]. One WT
and one NK1R−/− mouse were tested simultaneously, with
the same treatment and in adjacent LDEBs, to balance any
nuisance factors across the two genotypes. The procedure is
described fully in Fisher et al. (2007) and Herpfer et al. (2005).
Briefly, mice were allowed to habituate to the test room
between 10:00 and 13:00 h. At either 13:00 or 15:30 h, they
were confined individually within the DZ of the LDEB for
60 min, after which they were injected with their allocated
treatment, or left untreated (no injection, NI), and replaced
in the DZ for a further 30 min. The treatments were either
vehicle (0.9% saline, 10 mL·kg−1) or guanfacine (0.1, 0.3 or
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1.0 mg·kg−1, i.p.) (N = 5 per group), which were given in a
counterbalanced sequence; each mouse received only one
treatment. After a total of 90 min in the DZ, the mice were
transferred to the LZ and allowed to move freely between the
two zones. Behaviour was recorded by a digital video camera
for 30 min and scored later by an observer, unaware of the
treatments. Because the activity of mice in the LDEB declined
progressively to reach a ‘floor’ after approximately 15 min,
only the first 10 min of activity after transfer to the LZ were
used in the statistical analysis.
EPM
A third cohort of mice (from homozygous breeding pairs,
only) was tested in the EPM. Mice were allowed to habituate to
the test room between 10:00 and 14:00 h, and tested between
14:00 and 16:00 h on the EPM. They then received an i.p.
injection of vehicle (saline) or guanfacine (0.1 mg·kg−1),
30 min before testing, or received no injection (N = 5 per
group). Treatments were assigned in a counterbalanced order.
The mice were tested individually, by placing them at the
centre of the four arms, facing an open arm, after which they
were allowed to explore the maze for 5 min. The maze was
cleaned between each test with 70% ethanol. Behaviour was
recorded by a video camera, positioned above the maze and
was scored later by an observer, unaware of the treatments.
The following behavioural measures were recorded:
• %Time in open arms [time with all four paws in open
arms/(time on open arms + time on closed arms)] × 100
• %Time in centre; (time in centre/total time) × 100
• Number of whole-body entries; all four paws enter the arm
Data analysis
Statistical analyses were performed using InVivoStat (Clark
et al., 2012) and used raw or transformed data (arcsine,
log10(score+1) or square root), according to whichever opti-
mized the homogeneity of variance in the ‘predicted versus
residuals’ plot in InVivoStat. The ‘normal probability plot’ in
InVivoStat was used to examine whether or not the data were
normally distributed. If not, a rank transformation was
applied: that is, the data were assigned ranks, as for a non-
parametric analysis, but the ranks were then subjected to
parametric tests.
Repeated-measures analyses were used to examine data
from the 5-CSRTT. The analyses used a mixed model
approach: ‘within-animal’ correlations were modelled using a
compound symmetric covariance structure (which assumes
sphericity of the variance/covariance matrix). ‘Genotype’ and
‘colony’ were used as between-subject factors and ‘treatment’
was the within-subject factor. A fourth factor was ‘time of
day’ (i.e. AM session/PM session). Our previous studies indi-
cated that time of testing influences behaviour in the
5-CSRTT (Yan et al., 2011; Weir et al., 2014) and so this was
used as a blocking factor, to account for any additional vari-
ance in the data. This factor was collapsed across all subjects
if there was no effect of time of day on a given dependent
variable. A main effect of genotype or treatment, or an inter-
action between them, was used as the criterion for carrying
out post hoc pairwise comparisons.
In the LDEB and EPM, two-way ANOVAs were performed on
raw or transformed data, with the main factors genotype and
treatment. First, the ANOVA compared the factors across all
groups (uninjected, vehicle and drug treated). If there was a
main effect of either factor, or an interaction between them,
further analyses were carried out using post hoc ANOVA to
compare vehicle controls with drug treatment (main effect of
‘drug’). Where there was a main effect of genotype or drug, or
relevant interactions between the factors, post hoc LSD tests
were performed to compare pairs of data.
Materials
Guanfacine hydrochloride was purchased from Tocris (Abin-
gdon, UK), dissolved in 0.9% saline and injected i.p. in a
volume of 10 mL·kg−1 throughout.
Results
Our previous experiments have confirmed that repeated
experience of the VITI can influence behaviour in this test
(see Weir et al., 2014). For this reason, the response to guan-
facine in this study was compared with NI-2, which was
the uninjected control embedded within the series of drug
treatments. Findings from testing in NI-1 are to be reported
elsewhere.
Table 1
Performance variables recorded in the testing phase of the 5-CSRTT
Behavioural outcome Method of calculation
Total number of trials completed Total correct responses + total incorrect responses + total omissions
%Accuracy [correct responses/(correct + incorrect responses)] × 100
%Omissions [total omissions/total number of trials] × 100
%Premature responses [premature responses/(total number of trials + prems)] × 100
Latency to correct response Duration between onset of stimulus and a nose-poke in the correct hole
Latency to collect the reward Duration between a nose-poke in the correct hole and collection of reward from the magazine
Perseveration Number of unnecessary responses into the correct hole after the initial correct response, before
collection of reward, per 100 trials
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The 5-CSRTT experiment was carried out using mice
derived from two colonies (homozygous breeders and het-
erozygous breeders). However, there was no statistically sig-
nificant interaction between colony and the response to
vehicle or drug treatment, for any of the dependent variables,
and so the data were collapsed across colony.
As before (Yan et al., 2011; Weir et al., 2014), certain
behaviours (specifically, %omissions and %premature
responses) depended on time of day, which was used as a
blocking factor in the analysis of these behaviours. Where
there were no effects of time of day, data were collapsed across
this factor.
Guanfacine has bidirectional effects on
%omissions in NK1R−/− mice (Figure 1A)
There were no overall differences in %omissions between the
two genotypes [[sqrt, all groups] geno: F(1,18) = 3.40, P = 0.082]
(Figure 1A). The effects of guanfacine across all doses also did
not depend on genotype [[sqrt, veh vs. drug] drug*geno: F(3,49)
= 1.33, P = 0.276]. However, this drug had bidirectional effects
on this behaviour [[sqrt] drug: F(3,49) = 48.00, P < 0.001]. The
lowest dose (0.1 mg·kg−1) reduced %omissions in NK1R−/−
mice only, by comparison with either vehicle-treated
NK1R−/− mice [[sqrt] veh vs. 0.1 mg·kg−1: P = 0.004] or drug-
treated WTs [[sqrt] 0.1 mg·kg−1, WT vs. KO: P = 0.049]. The
highest dose of guanfacine (1.0 mg·kg−1) increased %omissions
in both genotypes to a similar extent [[sqrt] veh vs.
1.0 mg·kg−1, WT: P < 0.001, KO: P < 0.001].
Guanfacine attenuates premature responding
in WT and NK1R−/− mice (Figure 1B)
Overall, NK1R−/− mice expressed more %premature responses
than WTs [[sqrt, all groups] geno: F(1,18) = 8.39, P = 0.010]
(Figure 1B). Guanfacine reduced the incidence of this behav-
iour, [[sqrt, veh vs. drug] drug: F(3,49) = 9.45, P < 0.001], espe-
cially at the highest dose [[sqrt] veh vs. 1.0 mg·kg−1, WT: P =
0.012, KO: P < 0.001]. However, the effect of the drug did not
depend on genotype [[sqrt, veh vs. drug] drug*geno: F(3,49) =
0.39, P = 0.759].
Guanfacine blunts behaviour in measures of
arousal and motivation (Table 2)
Accuracy, total trials, latency to correct response and latency to the
magazine were all modified by guanfacine to the same extent
in both genotypes (Table 2). Whereas guanfacine decreased
%accuracy [[arcsine, veh vs. drug] drug: F(3,49) = 3.57, P = 0.020]
and total trials [[arcsine, veh vs. drug] drug: F(3,49) = 3.84, P =
0.015], latency to correct [[log10, veh vs. drug] drug: F(3,49) =
16.47, P < 0.001] and latency to magazine [[rank, veh vs. drug]
drug: F(3,49) = 39.42, P < 0.001] were both increased by the
drug.
Guanfacine reduces activity in the light/dark
exploration box (Figure 2)
Compared with untreated WTs, NK1R−/− mice were hyperac-
tive in the LZ of the LDEB [[sqrt, NI vs. veh] geno: F(1,16) = 4.75,
P = 0.044; NI, WT vs. KO: P = 0.024, Figure 2A]. An apparent
hyperactivity in the DZ just missed the criterion for statistical
significance [[sqrt, NI vs. veh] geno: F(1,16) = 3.79, P = 0.069,
Figure 2B].
Guanfacine reduced motor activity in the LZ [[rank, veh
vs. drug] drug: F(3,32) = 15.71, P < 0.001]: at the highest dose,
activity was decreased in both genotypes [[rank] veh vs.
1.0 mg·kg−1, WT: P = 0.007, NK1R−/−: P < 0.001, Figure 2A].
The same response was seen in the DZ [[sqrt, veh vs. drug]
drug: F(3,30) = 5.07, P = 0.006]. However, an apparent reduction
in locomotor activity in the DZ, after treatment with the
1.0 mg·kg−1 dose, was statistically significant in NK1R−/− mice
Figure 1
Effect of guanfacine (GFC; 0.1, 0.3 and 1.0 mg·kg−1, i.p.) on (A) %omissions and (B) %premature responses in the 5-CSRTT, compared with vehicle
(saline), or NI-2 in wild-type (WT) and NK1R−/− mice. The lowest dose of guanfacine reduced %omissions in NK1R−/− mice, but not WTs.
Guanfacine also decreased %premature responses, but to the same extent in both genotypes. Data show mean ± SEM. N = 9–10 per group. Lines
linking bars indicate statistical significance of at least P < 0.05; * indicates P < 0.05 versus vehicle within genotype.
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only [[sqrt] veh vs. 1.0 mg·kg−1, WT: P = 0.068, KO: P = 0.002;
Figure 2B]. Guanfacine also reduced the number of returns
to the LZ in both genotypes [[sqrt, veh vs. drug] drug:
F(3,32) = 4.99, P = 0.006; Figure 2C]. In NK1R−/− mice, this
response was evident at 0.1 and 1.0 mg·kg−1 [[sqrt] veh vs.
0.1 mg·kg−1: P = 0.017, veh vs. 1.0 mg·kg−1: P = 0.005] but only
the 1.0 mg·kg−1 dose caused such a reduction in WTs [[sqrt]
veh vs. 1.0 mg·kg−1: P = 0.023]. Overall, NK1R−/− mice spent
less time in the LZ than WTs [[rank, all groups] geno: F(1,32) =
4.75, P = 0.037] but this was unaffected by guanfacine [[rank,
veh vs. drug]drug: F(3,32) = 2.05, P = 0.127; Figure 2D]. The
effect of guanfacine did not depend on genotype in any
measure.
NK1R−/− mice display increased anxiety-like
behaviour in the EPM (Figure 3)
There was a clear difference in the behaviour of NK1R−/− and
WT mice in the EPM. Compared with WTs, NK1R−/− mice
spent less %time on the open arms [[raw, all groups] geno:
F(1,24) = 23.38, P < 0.001; Figure 3A] and made fewer entries
into the open arms [[rank, all groups] geno: F(1,24) = 42.32,
P < 0.001; Figure 3B]. There were no genotype differences in
the %time spent in the centre square [[raw, all groups] geno:
F(1,24) = 2.08, P = 0.1621; Figure 3C], or in the number of
entries to the closed arms [[sqrt, all groups] geno: F(1,24) = 2.64
P = 0.1171; Figure 3D].
When compared with vehicle-treated mice, guanfacine
had no overall effect on time in open arms [[raw, veh vs. drug]
drug: F(1,16) = 0.32, P = 0.578; Figure 3A], or the number of
entries to the open arms [[rank, veh vs. drug] drug: F(1,16) =
2.32, P = 0.147; Figure 3C]. The effect of guanfacine in the
two genotypes did not differ for either measure.
Discussion
The findings from this study suggest that, regardless of
colony, guanfacine improves attention and reduces impulsiv-
ity in NK1R−/− mice. A lack of any statistical interaction
between the factors ‘drug treatment’ and ‘colony’ renders it
unlikely that a difference in the response of the two colonies
is masking any effects of guanfacine on the behaviours
studied here.
Guanfacine improves ADHD-like behaviours
in NK1R−/− mice
Attention. Unlike our previous studies (Yan et al., 2011; Weir
et al., 2014), NK1R−/− mice did not display an inattentive
phenotype at baseline (NI-2) in this study. This could be a
result of improved performance after repeated testing (see
Weir et al., 2014), or relate to reports that individuals with
ADHD do not consistently present with the same behavioural
subtype (Lahey et al., 2005; Todd et al., 2008). Another factor
is that an increase in %omissions seems more robust when
animals are tested with a prolonged, but fixed, inter-trial
interval (LITI) than when using a variable ITI (unpublished
observations). However, a previous study has confirmed that
acute administration of an NK1 receptor antagonist (RP
67580) does aggravate inattentiveness in this test (Weir et al.,Ta
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Figure 2
Guanfacine (0.1, 0.3 and 1.0 mg·kg−1, i.p.) reduced activity of wild-type (WT) and NK1R−/− mice in both the light zone and dark zone, and
reduced crossings between the zones but had no effect on the time spent in either zone. (A) Activity per unit time in the light zone; (B) activity
per unit time in the dark zone ; (C) number of returns to the light zone; and (D) time in the light zone of a light–dark exploration box. NI, no
injection; Veh, vehicle (saline). Data show mean ± SEM, N = 5 per group. Lines linking bars indicate statistical significance of at least P < 0.05 and
* indicates P < 0.05 versus vehicle within genotype.
Figure 3
Guanfacine (GFC; 0.1 mg·kg−1) does not affect the behaviour of NK1R−/− mice in the EPM. (A) Time spent in the open arms; (B) number of entries
to the open arms; (C) %time spent in the centre section number; and (D) number of entries to the closed arms of an EPM in wild-type (white
bars) and NK1R−/− mice (grey bars). Data show mean ± SEM, N = 5. * P < 0.05.
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2014), suggesting that a lack of functional NK1 receptors
could contribute to this behavioural abnormality.
Nevertheless, the lowest dose of guanfacine studied in the
5-CSRTT (0.1 mg·kg−1) caused a modest (−7%) reduction in
%omissions (attention) in NK1R−/− mice, but not WTs. This
beneficial response is consistent with the improvement in
attention when spontaneously hypertensive rats (‘SHR’: a
long-established rodent model of ADHD) are tested in an
operant conditioning task (Sagvolden, 2006). This genotype-
specific improvement in attention in NK1R−/− mice is
unlikely to be explained by a change in animals’ state of
arousal or motivation to respond because, at this dose, guan-
facine did not affect the latency to correct response or the total
number of trials completed by either genotype.
Unfortunately, it is difficult to make quantitative com-
parisons of the response to guanfacine in this study and in
human trials because the scoring systems used in the two
fields differ considerably. However, one human study
has shown that when ADHD patients are tested in a
choice reaction–time test after guanfacine extended release
(GXR) treatment, they similarly show an improvement on
ADHD rating scales, but no reduction in reaction speed com-
pared with placebo (Kollins et al., 2011). An improved inat-
tention subscale score has also been reported in ADHD
patients after GXR treatment when given chronically
(Biederman et al., 2008; Sallee et al., 2009; 2012; Newcorn
et al., 2013) or in combination with a psychostimulant
(Wilens et al., 2012).
This genotype-dependent response to guanfacine is inter-
esting because it suggests that NK1R−/− mice are more sensi-
tive to the effects of a low dose of this drug. Given the
confirmed association of TACR1 gene polymorphism(s) and
ADHD, it is reasonable to predict that guanfacine could also
be more effective in ADHD patients with this genetic associa-
tion. Whether or not this is the case, it is not necessary for
guanfacine to be effective in only this genotype in order to be
an effective treatment for ADHD.
By contrast, the highest dose of guanfacine (1.0 mg·kg−1)
increased %omissions (i.e. reduced attention) in both geno-
types. This impairment is most likely explained by the well-
documented sedative effects of this drug (Van der Laan et al.,
1985; Jakala et al., 1999). This is because both the latency to
correct response and the latency to collect the reward were
increased, whereas the total number of total trials completed by
the mice was reduced at this dose. An alternative explanation
is that guanfacine blunted animals’ motivation to carry out
the task but, to the best of our knowledge, there is no evi-
dence that guanfacine impairs motivation. In either case, the
increase in %omissions is unlikely to be explained by a
primary effect on cognition.
In tests of vigilance and working memory, activation of
α2A-adrenoceptors enhances performance of both rats and
monkeys in delayed alternation (Carlson et al., 1992) and
delayed response tasks (Arnsten et al., 1988) respectively.
Conversely, depletion of cortical noradrenaline impairs sus-
tained attentional performance in the 5-CSRTT in rats (Carli
et al., 1983). Low doses of α2A-adrenoceptor agonists improve
performance, particularly in animals with either depletion of
cortical noradrenaline (Milstein et al., 2007) or in older
animals showing significant cortical loss of this neurotrans-
mitter (Arnsten et al., 1988). However, deficits in working
memory in mice with functional ablation of α2A-
adrenoceptors are not relieved by guanfacine (Franowicz
et al., 2002). Noradrenergic signalling strongly influences
frontal cortical regions that mediate attention and working
memory (see Arnsten and Li, 2005; Robbins and Roberts,
2007) and the classical bell-shaped treatment/response curve
applies (Aston-Jones and Cohen, 2005; Arnsten, 2011).
The beneficial effects of guanfacine are thought to be
mediated primarily by post-synaptic α2A-adrenoceptors
located in the prefrontal cortex (PFC), which may become
supersensitive as a consequence of a long-term deficit in
noradrenergic transmission (Omiya et al., 2008). However,
guanfacine could also reduce inattentiveness by activating
somatodendritic α2A-adrenoceptors in the locus coeruleus
(LC). This nucleus, which is the sole source of noradrenaline
in the PFC (Loughlin et al., 1982), receives inputs from both
GABAergic and glutamatergic projection neurones, from the
nucleus prepositus hypoglossi and nucleus paragigantocellu-
laris respectively (Ennis and Aston-Jones, 1989; Aston-Jones
et al., 1991). Whereas GABAergic neurones tonically inhibit
LC neurones, glutamate triggers their burst spiking in
response to sensory stimuli (Foote et al., 1980; Ennis and
Aston-Jones, 1989; Kawahara et al., 1999). Antagonism or
functional ablation of NK1 receptors blunts this GABAergic
inhibition (Maubach et al., 2002; Ebner and Singewald,
2007): such disinhibition would disrupt attention (Yan et al.,
2009) but could be prevented by activation of somatoden-
dritic α2A-adrenceptors, which suppresses LC excitation.
Accuracy is arguably an alternative index of attention
(Robbins, 2002), but there are disparate reports on the effects
of guanfacine on this measure. Whereas accuracy was
increased in one preclinical study of aged macaques (O’Neill
et al., 2000), there was no such response in a human study of
cognitive performance (Jakala et al., 1999). Here, accuracy was
not affected by any dose of guanfacine in either genotype,
probably because the performance of the animals in the
5-CSRTT was already near maximum for this measure (∼96%)
before drug treatment. One limitation of these findings is
that such a high level of accuracy prevents this from being a
useful index of attention when assessing the efficacy of the
low dose of guanfacine. However, it is unlikely that the
improvement in %omissions at the low dose is explained by
increased motivation because neither measure of motivation
(latency to correct response/reward) was affected.
Impulsivity. As in our previous studies, NK1R−/− mice were
more impulsive than WTs (Yan et al., 2011; Dudley et al.,
2013; Weir et al., 2014) but, here, this was evident only after
they had experienced an i.p. injection. The reason for this is
not clear but NK1 receptors are known to influence the
noradrenergic stress response (for reviews, see Ebner and
Singewald, 2006; Stanford, 2014). Guanfacine decreased
impulsivity in both WT and NK1R−/− mice: evidently, this
improvement (at 1.0 mg·kg−1) does not depend on functional
NK1 receptors but could be secondary to non-specific inhibi-
tion of motor behaviour. Nevertheless, such a non-specific
response could also explain the efficacy of this drug in the
clinic. If so, it is possible that motor impulsivity is more likely
to be attenuated than impulsive choice, such as the consid-
ered choosing of small, immediate rewards over larger,
delayed rewards (Bari and Robbins, 2013).
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Our findings are supported by evidence from other rodent
studies: for instance, a high dose of guanfacine decreased
impulsivity of both high-impulsive and low-impulsive rats in
the 5-CSRTT, but also increased inattentiveness and response
latencies (Fernando et al., 2012). Similarly, the response
control of rats in the stop signal reaction–time task was
improved by guanfacine, but this response was accompanied
by a reduction in the speed of reaction in the task (Bari et al.,
2009). In contrast, it was recently reported that local infusion
of guanfacine into the ventral hippocampus of rats caused an
improvement in impulsive choice, without affecting response
latencies (Abela and Chudasama, 2014).
Hyperactivity. As before, uninjected NK1R−/− mice were
hyperactive in the LDEB by comparison with WTs (Herpfer
et al., 2005; Fisher et al., 2007; Yan et al., 2010). This is con-
sistent with findings from our previous study in which acute
administration of the NK1 receptor antagonists L 733060 or
RP 67580 increased locomotor activity of wild-type mice (Yan
et al., 2010). This latter finding points to a lack of functional
NK1 receptors as a factor that underlies this behavioural
abnormality.
Guanfacine reduced locomotor activity in both genotypes
and so, like impulsivity, functional NK1 receptors are not
necessary for this response, and both are likely attributed to
the sedative effects of the drug (reviewed by Scheinin et al.,
1989). However, the greater reduction in activity and number
of returns to the LZ in NK1R−/− mice suggests that these mice
could be more sensitive to the actions of guanfacine.
In the clinic, somnolence, sedation and fatigue are the
most frequent reasons for discontinuing guanfacine therapy
(Faraone et al., 2013; Hirota et al., 2014). Notwithstanding
the confounding effects of sedation on measures of impulsiv-
ity, numerous preclinical studies have dissociated the sedative
and cognitive effects of α2-adrenoceptor agonists (Arnsten
et al., 1988; Franowicz and Arnsten, 1998; Jakala et al., 1999).
For instance, the spatial working memory of rhesus monkeys
was improved at a dose of guanfacine that had no sedative or
hypotensive effects (Arnsten et al., 1988).
NK1R−/− mice display an
anxiogenic phenotype
Anxiety is a common co-morbid problem for ADHD patients
(Sobanski, 2006), and the two disorders may interact. For
instance, Mancini et al. (1999) reported that the age of onset
of anxiety is earlier, and its severity greater, in patients who
had experienced childhood ADHD. Furthermore, ADHD
patients with co-morbid anxiety have more pronounced
attentional deficits (Sobanski, 2006).
Although the LZ of the LDEB was configured so as to
render it ‘novel’, rather than aversive (i.e. low light intensity),
these NK1R−/− mice (on a mixed background) displayed
greater anxiety-like behaviour by comparison with their wild-
types. This finding is consistent with our previous reports
that NK1R−/− mice express greater active and passive avoid-
ance of the LZ of the LDEB (Herpfer et al., 2005; Fisher et al.,
2007). Nevertheless, the LDEB protocol used here has not
been validated as a screen for anxiolytic drugs. For this
reason, we also compared the behaviour of NK1R−/− and
WT mice in the EPM. In this procedure, the NK1R−/− mice
spent less time (∼17 vs. 44% in WTs) on the open arms and
made fewer entries to the open arms, confirming that the
NK1R−/− phenotype expresses more anxiety-like behaviour
than WTs.
The effect of functional ablation of the NK1 receptor gene
on anxiety-like behaviour and locomotor activity seems to
depend on genetic background. This is inferred from evi-
dence that mice lacking NK1 receptors on a 129/SvEv back-
ground spend a greater proportion of time on the open arms
of an EPM than their WTs (i.e. they express less anxiety-like
behaviour; Santarelli et al., 2001). By contrast, NK1R−/− mice
on either a 129/Sv × C57BL/6 background (Murtra et al.,
2000) or a J129/C57 hybrid background (Rupniak et al., 2001)
do not. In fact, compared with WTs, NK1R−/− mice on a
129/Sv × C57BL/6 background spent less time on the EPM
open arms (Gadd et al., 2003), an action that is consistent
with increased anxiety-like behaviour. Furthermore, as we
have reported previously (see above), mice from this colony
display hyperactivity, compared with WTs, whereas for
C57Bl6 mice, there is no such genotype difference
(McCutcheon et al., 2008). It would be interesting to learn
whether the abnormal locomotor activity and cognitive per-
formance of NK1R−/− mice are similarly affected by back-
ground strain.
Guanfacine did not affect anxiety-like behaviour of either
genotype in either the LDEB or the EPM test, at any dose. This
finding contrasts with a report that this drug reduces anxiety-
like behaviour of SHR, but not Wistar or WKY control rats, in
the EPM (Langen and Dost, 2011). However, reports of the
efficacy of guanfacine as an anxiolytic are inconsistent,
despite its use for this clinical indication (Neylan et al., 2006;
but see Connor et al., 2013). Nevertheless, the important
finding here is that the effects of this drug on the behaviour
expressed by NK1R−/− mice in the 5-CSRTT are unlikely to be
secondary to a change in animals’ emotional status.
Conclusions
The effects of guanfacine on the behaviour of NK1R−/− mice
in the 5-CSRTT closely resemble its clinical profile in ADHD
patients. The finding that guanfacine can improve attention,
without affecting impulsivity, supports our proposal that
impulsivity and attention are underpinned by different
neuronal networks (Dudley et al., 2013; Stanford, 2014).
However, this distinctive response was evident only at the
lowest dose of guanfacine, suggesting that, at higher drug
doses, its influence on these networks is either less selective,
or that the networks interact.
Because guanfacine did not affect anxiety-like behaviour
at any dose, it is unlikely that the response to this drug is
confounded by an underlying difference in co-morbid
anxiety in NK1R−/− mice. Nevertheless, the influence of back-
ground strain on anxiety-like behaviour implies that modu-
lation of this abnormal behaviour rests on an interaction
between the NK1 receptor gene and other gene(s), or epige-
netic factor(s), as yet unidentified. Such an influence is
potentially clinically important because anxiety is a
common co-morbid problem for ADHD patients (Sobanski,
2006). In light of these findings, the possibility that TACR1
BJPGuanfacine in the NK1R−/− mouse model of ADHD
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polymorphism(s) contribute to co-morbid anxiety in ADHD
patients merits further investigation.
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